Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia
Pneumonia
About this trial
This is an interventional treatment trial for Pneumonia focused on measuring Community-Acquired Pneumonia, Cephalosporins, Methicillin-Resistant Staphylococcus Aureus
Eligibility Criteria
Inclusion Criteria: Patients suffering from community-acquired pneumonia severe enough to require hospitalization Female patients must be postmenopausal for at least 1 year, surgically sterile, or practicing an effective method of birth control before entry and throughout the study Exclusion Criteria: Patients with known or suspected hypersensitivity to any related antibiotic medications Treatment with any experimental drug within 30 days before enrollment Prior enrollment in this study or any study with ceftobiprole medocaril
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Ceftobiprole medocaril
Ceftriaxone with or without Linezolid
Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
Ceftriaxone 2g qd as 0.5h infusions with or without Linezolid 600mg q12h as 1h infusions, 7-14d